摘要
目的:观察卡培他滨(希罗达)联合草酸铂作为一线方案治疗晚期大肠癌的临床疗效和可耐受性.方法:53例晚期大肠癌患者采用希罗达1 250 mg/(m2 *d)口服,第1～14天,草酸铂 130 mg/(m2 *d)静滴第1天,21天1周期,连用2周期以上评价疗效.结果:CR 8例,PR 20例,总有效率(CR+PR)为52.8%.毒副作用主要为Ⅰ～Ⅱ级恶心、呕吐、腹泻、口炎、末梢神经异常及白细胞减少.结论:卡培他宾联合草酸铂治疗晚期大肠癌疗效较高,安全性好,副作用可耐受,值得进一步临床观察.
Objectlve：To determine the efficacy and tolerability of capecitabine combined with oxaliplatin as first-line treatment in advanced colorectal cancer. Methods：53 patients of advanced colorectal cancer were treated with capecitabine 1250 mg/m^2·d, Po,d1-14, Oxaliplatin 130 mg/m^2·d iv gtt dI,repeated every 3 weeks （one cycle）. The effect was evaluated after two cycles. Results：Complete response in 8 pts and partial response in 20 pts were observed with an overall response rate of 52.8%. Adverse effects were mainly grade Ⅰ - Ⅱ ,including nausea and vomiting in 18 pts （33.9%） , stomatitis in 10（ 18.9% ）, and hand-foot syndrome （HFS） in 5 pts（9.4% ） , respectively. Concluslon：Combining capecitabine and oxaliplatin is an effective and better-tolerated alternative treatment in advanced colorectal cancer and yields promising activity.
出处
《临床肿瘤学杂志》
CAS
2005年第2期180-182,共3页
Chinese Clinical Oncology
关键词
晚期大肠癌
卡培他滨
草酸铂
联合化疗
Advanced colorectal cancer
Capecitabine
Oxaliplatin
Combination chemotherapy
